New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma in early trial
Disease control
Not yet recruiting
This early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC